JPMorgan Chase & Co. Reaffirms Overweight Rating for AstraZeneca (LON:AZN)

Legend Biotech (NASDAQ:LEGN – Get Rating) had its price objective boosted by investment analysts at HC Wainwright from $77.00 to $82.00 in a report released on Tuesday, The Fly reports. HC Wainwright’s target price would suggest a potential upside of 20.23% from the stock’s current price. Several other equities analysts have also recently issued reports […]

Related Keywords

China ,Quebec ,Canada ,United States ,William Blair ,Legend Biotech Corporation ,China Universal Asset Management Co ,Royal Bank ,Asset Management One Co ,Mitsubishi Ufj ,Legend Biotech Company Profile ,Banking Corp ,Krane Funds Advisors ,Legend Biotech ,Get Rating ,Capital Markets ,Universal Asset Management ,Management One ,Funds Advisors ,Biotech Corporation ,Legend Biotech Daily ,Nasdaq Legn ,Legn ,Medical ,Boost Price Target ,Hc Wainwright ,